Coreg (carvedilol) NDC 80725-139

NDC codes

FDA NDC Directory

Product NDC (as listed)80725-139Labeler and product segments. Claims need a package NDC.

Product NDC at billing width80725-0139Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
80725-139-20	80725013920	100 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (80725-139-20)Marketed from Apr 15, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Coreg
Generic name (nonproprietary): carvedilol
Active ingredients: Carvedilol — 3.125 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Waylis Therapeutics LLC
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 020297
Marketing start: Mar 15, 2023
Listing expires: Dec 31, 2027
Other FDA classes: Adrenergic alpha-Antagonists (Mechanism)Adrenergic beta1-Antagonists (Mechanism)Adrenergic beta2-Antagonists (Mechanism)
Identifiers: Product ID 80725-139_514a36dd-5646-48b3-99cc-1457af6cb7d8SPL ID 514a36dd-5646-48b3-99cc-1457af6cb7d8SPL set ID 07c619c6-4a0c-445e-94fa-664a54f68a39RxCUI 200031, 200032, 200033, 212388, 212389, 212390, 686924, 686926UNII 0K47UL67F2UPC 0380725142200, 0380725141203, 0380725140206, 0380725139200
Pharmacologic class: alpha-Adrenergic Blocker; beta-Adrenergic Blocker

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N480725013920 followed by a unit qualifier and the quantity

Package 80725-0139-20. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 31, 2026.

Indications (excerpt from the label)

1. INDICATIONS AND USAGE COREG is an alpha-/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients ( 1.2 ) hypertension ( 1.3 ) 1.1 Heart Failure COREG is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions (7.4) , Clinical Studies (14.1) ]. 1.2 Left Ventricular Dysfunction following Myocardial Infarction COREG is indicated to reduce cardiov…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 020297

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 020297
Product	Strength	Form · route	Labeler	Product NDC
Coregcarvedilol	Carvedilol 25 mg/1	Tablet, Film coatedOral	Waylis Therapeutics LLC	80725-142
Coregcarvedilol	Carvedilol 6.25 mg/1	Tablet, Film coatedOral	Waylis Therapeutics LLC	80725-140
Coregcarvedilol	Carvedilol 12.5 mg/1	Tablet, Film coatedOral	Waylis Therapeutics LLC	80725-141